U.S. Markets closed

Sarepta Therapeutics Has Returned 169.97% Year-to-Date

Margaret Patrick
Sarepta Therapeutics Has Returned 169.97% Year-to-Date

Sarepta Therapeutics (SRPT) has returned 169.97% YTD (year-to-date). In the second quarter, it reported EPS of -$0.43, surpassing the consensus estimate by $0.46. EXONDYS 51 sales were $73.5 million in the quarter, which is a YoY (year-over-year) rise of 110%. Wall Street analysts have projected a 12-month consensus target price of $188.58, which is a 25.54% rise over its closing price on September 13. By the end of 2018, Sarepta Therapeutics plans to submit a rolling NDA (New Drug Application) to the FDA for golodirsen, an investigational phosphorodiamidate Morpholino oligomer (or PMO) therapy, in Duchenne muscular dystrophy (or DMD) due to deletions in the DMD gene related to exon 53 skipping.